Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $14.00.

Several brokerages recently issued reports on CNAT. HC Wainwright restated a “buy” rating and issued a $17.00 target price (down previously from $18.00) on shares of Conatus Pharmaceuticals in a report on Thursday, November 2nd. Seaport Global Securities restated a “buy” rating and issued a $16.00 target price on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Finally, Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd.

Shares of Conatus Pharmaceuticals (CNAT) traded down $0.33 during mid-day trading on Tuesday, reaching $4.68. 596,800 shares of the company traded hands, compared to its average volume of 322,140. Conatus Pharmaceuticals has a 52 week low of $3.88 and a 52 week high of $9.40. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $140.43, a PE ratio of -5.78 and a beta of 1.10.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The company had revenue of $9.57 million during the quarter, compared to analysts’ expectations of $16.06 million. During the same quarter in the prior year, the business posted ($0.31) EPS. analysts predict that Conatus Pharmaceuticals will post -0.65 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. Voya Investment Management LLC purchased a new stake in Conatus Pharmaceuticals in the second quarter worth approximately $101,000. Bank of Montreal Can purchased a new position in shares of Conatus Pharmaceuticals during the 2nd quarter worth $109,000. Wells Fargo & Company MN boosted its stake in shares of Conatus Pharmaceuticals by 3,098.0% during the 3rd quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 18,588 shares during the last quarter. FNY Partners Fund LP boosted its stake in shares of Conatus Pharmaceuticals by 98.0% during the 2nd quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 9,800 shares during the last quarter. Finally, State of Wisconsin Investment Board purchased a new position in shares of Conatus Pharmaceuticals during the 2nd quarter worth $115,000. Institutional investors own 36.84% of the company’s stock.

WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/conatus-pharmaceuticals-inc-cnat-given-average-rating-of-buy-by-brokerages/1799866.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.